nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Adverse reaction—Riluzole—amyotrophic lateral sclerosis	0.0573	0.0677	CcSEcCtD
Methylphenidate—Reaction aggravation—Riluzole—amyotrophic lateral sclerosis	0.0573	0.0677	CcSEcCtD
Methylphenidate—Cardiac murmur—Riluzole—amyotrophic lateral sclerosis	0.0194	0.0229	CcSEcCtD
Methylphenidate—Dental caries—Riluzole—amyotrophic lateral sclerosis	0.0161	0.0191	CcSEcCtD
Methylphenidate—Personality disorder—Riluzole—amyotrophic lateral sclerosis	0.0139	0.0164	CcSEcCtD
Methylphenidate—Thrombocytopenic purpura—Riluzole—amyotrophic lateral sclerosis	0.0128	0.0151	CcSEcCtD
Methylphenidate—Hernia—Riluzole—amyotrophic lateral sclerosis	0.0128	0.0151	CcSEcCtD
Methylphenidate—Priapism—Riluzole—amyotrophic lateral sclerosis	0.0124	0.0147	CcSEcCtD
Methylphenidate—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0145	CcSEcCtD
Methylphenidate—SLC6A3—nerve—amyotrophic lateral sclerosis	0.0115	0.126	CbGeAlD
Methylphenidate—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0109	0.0128	CcSEcCtD
Methylphenidate—Hostility—Riluzole—amyotrophic lateral sclerosis	0.0109	0.0128	CcSEcCtD
Methylphenidate—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0125	CcSEcCtD
Methylphenidate—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0121	CcSEcCtD
Methylphenidate—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0119	CcSEcCtD
Methylphenidate—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00957	0.0113	CcSEcCtD
Methylphenidate—SLC6A2—nerve—amyotrophic lateral sclerosis	0.0093	0.102	CbGeAlD
Methylphenidate—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00918	0.0108	CcSEcCtD
Methylphenidate—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00918	0.0108	CcSEcCtD
Methylphenidate—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00863	0.0944	CbGeAlD
Methylphenidate—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.00857	0.0101	CcSEcCtD
Methylphenidate—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00842	0.00994	CcSEcCtD
Methylphenidate—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00834	0.00985	CcSEcCtD
Methylphenidate—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00834	0.00985	CcSEcCtD
Methylphenidate—Mania—Riluzole—amyotrophic lateral sclerosis	0.00827	0.00976	CcSEcCtD
Methylphenidate—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00798	0.00943	CcSEcCtD
Methylphenidate—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00791	0.0865	CbGeAlD
Methylphenidate—SLC6A4—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.00785	0.127	CbGpPWpGaD
Methylphenidate—Abscess—Riluzole—amyotrophic lateral sclerosis	0.0076	0.00897	CcSEcCtD
Methylphenidate—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00731	0.00863	CcSEcCtD
Methylphenidate—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00699	0.00826	CcSEcCtD
Methylphenidate—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00679	0.00803	CcSEcCtD
Methylphenidate—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00666	0.00786	CcSEcCtD
Methylphenidate—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00666	0.00786	CcSEcCtD
Methylphenidate—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00657	0.00776	CcSEcCtD
Methylphenidate—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00657	0.00776	CcSEcCtD
Methylphenidate—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00636	0.00751	CcSEcCtD
Methylphenidate—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00636	0.00751	CcSEcCtD
Methylphenidate—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00609	0.00719	CcSEcCtD
Methylphenidate—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00601	0.0071	CcSEcCtD
Methylphenidate—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00601	0.0071	CcSEcCtD
Methylphenidate—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00594	0.00702	CcSEcCtD
Methylphenidate—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00594	0.00702	CcSEcCtD
Methylphenidate—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00564	0.00667	CcSEcCtD
Methylphenidate—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00552	0.00652	CcSEcCtD
Methylphenidate—Coma—Riluzole—amyotrophic lateral sclerosis	0.00549	0.00649	CcSEcCtD
Methylphenidate—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00544	0.00642	CcSEcCtD
Methylphenidate—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00544	0.00642	CcSEcCtD
Methylphenidate—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00522	0.00616	CcSEcCtD
Methylphenidate—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00517	0.0061	CcSEcCtD
Methylphenidate—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00512	0.00604	CcSEcCtD
Methylphenidate—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00512	0.00604	CcSEcCtD
Methylphenidate—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00502	0.00593	CcSEcCtD
Methylphenidate—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00502	0.00593	CcSEcCtD
Methylphenidate—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00499	0.0059	CcSEcCtD
Methylphenidate—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00497	0.00587	CcSEcCtD
Methylphenidate—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00495	0.0541	CbGeAlD
Methylphenidate—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00486	0.00574	CcSEcCtD
Methylphenidate—Injury—Riluzole—amyotrophic lateral sclerosis	0.00475	0.00561	CcSEcCtD
Methylphenidate—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00471	0.00556	CcSEcCtD
Methylphenidate—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00465	0.00549	CcSEcCtD
Methylphenidate—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00463	0.00546	CcSEcCtD
Methylphenidate—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00459	0.00542	CcSEcCtD
Methylphenidate—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00453	0.0496	CbGeAlD
Methylphenidate—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00436	0.00515	CcSEcCtD
Methylphenidate—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00433	0.00511	CcSEcCtD
Methylphenidate—Migraine—Riluzole—amyotrophic lateral sclerosis	0.0043	0.00507	CcSEcCtD
Methylphenidate—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.0043	0.00507	CcSEcCtD
Methylphenidate—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00426	0.00503	CcSEcCtD
Methylphenidate—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00415	0.0049	CcSEcCtD
Methylphenidate—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00413	0.00488	CcSEcCtD
Methylphenidate—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00406	0.00479	CcSEcCtD
Methylphenidate—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00403	0.00476	CcSEcCtD
Methylphenidate—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00399	0.0437	CbGeAlD
Methylphenidate—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00394	0.00466	CcSEcCtD
Methylphenidate—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00456	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00385	0.00455	CcSEcCtD
Methylphenidate—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00381	0.0417	CbGeAlD
Methylphenidate—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00445	CcSEcCtD
Methylphenidate—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00445	CcSEcCtD
Methylphenidate—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.0037	0.00437	CcSEcCtD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—ATXN2—amyotrophic lateral sclerosis	0.0037	0.0597	CbGpPWpGaD
Methylphenidate—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00434	CcSEcCtD
Methylphenidate—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00363	0.00428	CcSEcCtD
Methylphenidate—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00427	CcSEcCtD
Methylphenidate—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00358	0.00423	CcSEcCtD
Methylphenidate—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00347	0.0041	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00344	0.00407	CcSEcCtD
Methylphenidate—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00343	0.00405	CcSEcCtD
Methylphenidate—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00341	0.00403	CcSEcCtD
Methylphenidate—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00338	0.004	CcSEcCtD
Methylphenidate—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00397	CcSEcCtD
Methylphenidate—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00397	CcSEcCtD
Methylphenidate—Depression—Riluzole—amyotrophic lateral sclerosis	0.00335	0.00396	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00332	0.00392	CcSEcCtD
Methylphenidate—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.0033	0.00389	CcSEcCtD
Methylphenidate—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00381	CcSEcCtD
Methylphenidate—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00379	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00376	CcSEcCtD
Methylphenidate—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00375	CcSEcCtD
Methylphenidate—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00316	0.0511	CbGpPWpGaD
Methylphenidate—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00373	CcSEcCtD
Methylphenidate—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00308	0.0337	CbGeAlD
Methylphenidate—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00363	CcSEcCtD
Methylphenidate—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00358	CcSEcCtD
Methylphenidate—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00357	CcSEcCtD
Methylphenidate—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00302	0.00357	CcSEcCtD
Methylphenidate—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.003	0.00355	CcSEcCtD
Methylphenidate—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.003	0.00354	CcSEcCtD
Methylphenidate—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00298	0.00352	CcSEcCtD
Methylphenidate—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00297	0.0035	CcSEcCtD
Methylphenidate—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0035	CcSEcCtD
Methylphenidate—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00285	0.00337	CcSEcCtD
Methylphenidate—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00333	CcSEcCtD
Methylphenidate—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00282	0.0308	CbGeAlD
Methylphenidate—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.0028	0.0453	CbGpPWpGaD
Methylphenidate—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00331	CcSEcCtD
Methylphenidate—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00278	0.0305	CbGeAlD
Methylphenidate—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00324	CcSEcCtD
Methylphenidate—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00322	CcSEcCtD
Methylphenidate—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00272	0.00321	CcSEcCtD
Methylphenidate—Chills—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0032	CcSEcCtD
Methylphenidate—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00319	CcSEcCtD
Methylphenidate—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00315	CcSEcCtD
Methylphenidate—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00265	0.00312	CcSEcCtD
Methylphenidate—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00263	0.0031	CcSEcCtD
Methylphenidate—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00259	0.0284	CbGeAlD
Methylphenidate—Tension—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00305	CcSEcCtD
Methylphenidate—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00301	CcSEcCtD
Methylphenidate—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00254	0.003	CcSEcCtD
Methylphenidate—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00298	CcSEcCtD
Methylphenidate—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.0025	0.0273	CbGeAlD
Methylphenidate—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00291	CcSEcCtD
Methylphenidate—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00244	0.0267	CbGeAlD
Methylphenidate—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00288	CcSEcCtD
Methylphenidate—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00287	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00242	0.0392	CbGpPWpGaD
Methylphenidate—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00285	CcSEcCtD
Methylphenidate—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00284	CcSEcCtD
Methylphenidate—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00237	0.026	CbGeAlD
Methylphenidate—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00237	0.0028	CcSEcCtD
Methylphenidate—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00279	CcSEcCtD
Methylphenidate—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00278	CcSEcCtD
Methylphenidate—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00278	CcSEcCtD
Methylphenidate—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00274	CcSEcCtD
Methylphenidate—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00273	CcSEcCtD
Methylphenidate—Cough—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00271	CcSEcCtD
Methylphenidate—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00229	0.025	CbGeAlD
Methylphenidate—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00269	CcSEcCtD
Methylphenidate—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00268	CcSEcCtD
Methylphenidate—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00264	CcSEcCtD
Methylphenidate—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00264	CcSEcCtD
Methylphenidate—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00264	CcSEcCtD
Methylphenidate—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00263	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00262	CcSEcCtD
Methylphenidate—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00261	CcSEcCtD
Methylphenidate—SLC6A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00219	0.0355	CbGpPWpGaD
Methylphenidate—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00258	CcSEcCtD
Methylphenidate—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00219	0.0239	CbGeAlD
Methylphenidate—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00255	CcSEcCtD
Methylphenidate—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00253	CcSEcCtD
Methylphenidate—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00253	CcSEcCtD
Methylphenidate—Infection—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00252	CcSEcCtD
Methylphenidate—Shock—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00249	CcSEcCtD
Methylphenidate—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00248	CcSEcCtD
Methylphenidate—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00248	CcSEcCtD
Methylphenidate—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00247	CcSEcCtD
Methylphenidate—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00209	0.0229	CbGeAlD
Methylphenidate—SLC6A2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00208	0.0337	CbGpPWpGaD
Methylphenidate—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00246	CcSEcCtD
Methylphenidate—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00245	CcSEcCtD
Methylphenidate—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00241	CcSEcCtD
Methylphenidate—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00201	0.022	CbGeAlD
Methylphenidate—SLC6A4—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00199	0.0321	CbGpPWpGaD
Methylphenidate—SLC6A3—brain—amyotrophic lateral sclerosis	0.00198	0.0217	CbGeAlD
Methylphenidate—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00231	CcSEcCtD
Methylphenidate—SLC6A3—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00194	0.0314	CbGpPWpGaD
Methylphenidate—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00229	CcSEcCtD
Methylphenidate—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00227	CcSEcCtD
Methylphenidate—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00226	CcSEcCtD
Methylphenidate—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00225	CcSEcCtD
Methylphenidate—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00223	CcSEcCtD
Methylphenidate—SLC6A4—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00187	0.0303	CbGpPWpGaD
Methylphenidate—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00186	0.0022	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00219	CcSEcCtD
Methylphenidate—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00218	CcSEcCtD
Methylphenidate—SLC6A3—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00185	0.0298	CbGpPWpGaD
Methylphenidate—Pain—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00217	CcSEcCtD
Methylphenidate—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00217	CcSEcCtD
Methylphenidate—SLC6A4—brain—amyotrophic lateral sclerosis	0.00182	0.0199	CbGeAlD
Methylphenidate—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00209	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00207	CcSEcCtD
Methylphenidate—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00201	CcSEcCtD
Methylphenidate—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0017	0.002	CcSEcCtD
Methylphenidate—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.0017	0.002	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.00163	0.0263	CbGpPWpGaD
Methylphenidate—SLC6A2—brain—amyotrophic lateral sclerosis	0.0016	0.0175	CbGeAlD
Methylphenidate—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00187	CcSEcCtD
Methylphenidate—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00182	CcSEcCtD
Methylphenidate—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00179	CcSEcCtD
Methylphenidate—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00173	CcSEcCtD
Methylphenidate—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00168	CcSEcCtD
Methylphenidate—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00161	CcSEcCtD
Methylphenidate—Rash—Riluzole—amyotrophic lateral sclerosis	0.00135	0.0016	CcSEcCtD
Methylphenidate—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00135	0.0016	CcSEcCtD
Methylphenidate—Headache—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00159	CcSEcCtD
Methylphenidate—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00127	0.0015	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00119	0.0192	CbGpPWpGaD
Methylphenidate—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00114	0.0125	CbGeAlD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP9—amyotrophic lateral sclerosis	0.00111	0.0179	CbGpPWpGaD
Methylphenidate—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.0011	0.0121	CbGeAlD
Methylphenidate—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00108	0.0118	CbGeAlD
Methylphenidate—SLC6A4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000983	0.0159	CbGpPWpGaD
Methylphenidate—CYP2D6—brain—amyotrophic lateral sclerosis	0.000875	0.00958	CbGeAlD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000858	0.0139	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000846	0.0137	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000766	0.0124	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000766	0.0124	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000766	0.0124	CbGpPWpGaD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00076	0.0123	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000749	0.0121	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00072	0.0116	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.000631	0.0102	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000619	0.01	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.000582	0.00941	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000562	0.00909	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000555	0.00896	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000548	0.00886	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000528	0.00853	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000515	0.00832	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000514	0.00831	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000484	0.00781	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000478	0.00773	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000478	0.00773	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000477	0.00771	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.000467	0.00754	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000456	0.00737	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000446	0.00721	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000438	0.00707	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000434	0.00701	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000431	0.00696	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000427	0.00689	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000426	0.00689	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000423	0.00683	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000406	0.00656	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000396	0.0064	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000394	0.00637	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00039	0.0063	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000388	0.00626	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000373	0.00603	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000366	0.00592	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000366	0.00592	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00036	0.00581	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000346	0.00558	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000331	0.00534	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000327	0.00528	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000304	0.0049	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000262	0.00423	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000232	0.00374	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000222	0.00359	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000222	0.00359	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000198	0.0032	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000198	0.0032	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000197	0.00318	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000197	0.00318	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000176	0.00284	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000168	0.00271	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000136	0.00219	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000134	0.00216	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000104	0.00168	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000104	0.00168	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000104	0.00167	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	9.52e-05	0.00154	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.85e-05	0.00143	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	8.32e-05	0.00134	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	7.53e-05	0.00122	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	5.7e-05	0.000921	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	5.26e-05	0.00085	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	4.32e-05	0.000698	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.32e-05	0.000375	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.13e-05	0.000345	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.76e-05	0.000284	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.2e-05	0.000194	CbGpPWpGaD
